Cardiol Therapeutics (CRDL) EPS (Weighted Average and Diluted) (2020 - 2022)

Cardiol Therapeutics has reported EPS (Weighted Average and Diluted) for 3 years, with the latest figure at -$0.15 in Q4 2022.

• For the quarter ending Q4 2022, EPS (Weighted Average and Diluted) rose 51.98% year-over-year to -$0.15; the trailing twelve-month figure through Dec 2025 stood at -$0.3 (up 31.24% YoY), and the FY2025 full-year result was -$0.28, up 23.4% from the prior year.
• EPS (Weighted Average and Diluted) for Q4 2022 stood at -$0.15, up from -$0.3 in the prior quarter.
• The five-year high for EPS (Weighted Average and Diluted) was -$0.15 in Q4 2022, with the low at -$0.32 in Q4 2020.
• Historically, EPS (Weighted Average and Diluted) has averaged -$0.26 across 3 years, with a median of -$0.3 in 2021.
• Annual changes were most pronounced in 2021 — EPS (Weighted Average and Diluted) gained 5.94% — and 2022, when it jumped 51.98%.
• Cardiol Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.32 in 2020, then climbed by 5.94% to -$0.3 in 2021, then jumped by 51.98% to -$0.15 in 2022.
• The last three EPS (Weighted Average and Diluted) figures came in at -$0.15 (Q4 2022), -$0.3 (Q4 2021), and -$0.32 (Q4 2020), per Business Quant data.